{"id":"W3004193413","doi":"10.1128/aac.00099-20","title":"Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018)","year":2020,"lang":"en","type":"article","venue":"Antimicrobial Agents and Chemotherapy","topic":"Antifungal resistance and susceptibility","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"bioMérieux; Dr. Falk Pharma; Idorsia Pharmaceuticals; Wockhardt; TenNor Therapeutics; Astellas Foundation for Research on Metabolic Disorders; Shionogi; Basilea Pharmaceutica; Astellas Pharma; Pfizer; Melinta Therapeutics; Entasis Therapeutics; Albany College of Pharmacy and Health Sciences; Achaogen; U.S. Food and Drug Administration; Amplyx; University of North Texas; Medicines Company; Roivant Sciences; Nabriva Therapeutics; BD; GenePOC; Boston Pharmaceuticals; Novartis; Harvard University; F. Hoffmann-La Roche; Allergan; Cidara Therapeutics; University of Southern California; GlaxoSmithKline; Bayer","keywords":"Echinocandin; Anidulafungin; Microbiology; Candida dubliniensis; Candida parapsilosis; Candida krusei; Candida tropicalis; Broth microdilution; Candida glabrata; Biology; Micafungin; Caspofungin; Fluconazole; Aspergillus fumigatus; Cryptococcus neoformans; Candida albicans; Corpus albicans; Minimum inhibitory concentration; Antimicrobial; Antifungal","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006133699,0.0003034203,0.0005230979,0.0004330515,0.0001257564,0.0004341785,0.0003144694,0.0002691405,0.0008379235],"category_scores_gemma":[0.001079182,0.00008513678,0.0002896004,0.0004541633,0.0001661289,0.0003707551,0.0002033238,0.0003823501,0.000115005],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002956672,"about_ca_system_score_gemma":0.0003499093,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001096726,"about_ca_topic_score_gemma":0.00245268,"domain_scores_codex":[0.9994758,0.00009302801,0.00008971194,0.0001274733,0.000169722,0.00004437904],"domain_scores_gemma":[0.9992773,0.0001088392,0.0003541208,0.00004043648,0.0001410514,0.00007819203],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0144622,0.003350226,0.1900937,0.0009934,0.0005614776,0.001010096,0.000433866,0.001610559,0.6014268,0.0002110712,0.0005423531,0.1853043],"study_design_scores_gemma":[0.001524986,0.09849458,0.6001617,0.0002247049,0.000882326,0.006107286,0.0005646776,0.002133775,0.2732375,0.0001237874,0.01647093,0.00007369663],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9953843,0.003172505,0.0001722992,0.00005280429,0.00001389091,0.00005017952,0.0003890138,0.000008491279,0.0007565344],"genre_scores_gemma":[0.9963961,0.001373753,0.0009283885,0.00005067976,0.00002473041,0.00002207069,0.0008281496,0.000002654338,0.0003735924],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001096726,"threshold_uncertainty_score":0.003243864,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04492092114504406,"score_gpt":0.30234790266308,"score_spread":0.2574269815180359,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}